Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-8797 tablets, which will conduct clinical trials in the near future.

HRS-8797 tablets are a class 1 innovative drug for the treatment of atopic dermatitis independently developed by the company. After inquiry, no similar drug has been approved for marketing worldwide. Up to now, the total R&D investment for HRS-8797 film-related projects is approximately RMB 32.9 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.